11 Best Value Stocks to Buy Now
On February 7, Richard Bernstein, the CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the current state of the equity markets and his firm's macro-driven investment strategy...
Bristol Myers Squibb Co (BMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 25,796,905 | $1,391,485,051 | +173% | 0.73% |
| 2. | Pzena Investment Management Richard S. Pzena | 17,943,503 | $967,872,552 | +21% | 2.9% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 17,190,560 | $927,258,806 | +16% | 0.54% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 10,844,270 | $584,939,925 | +608% | 0.53% |
| 5. | GLG Partners Noam Gottesman | 8,317,538 | $448,647,999 | -10% | 0.76% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.58 | 4,250 | $202,215.00 | 83,513 | 2025-04-25 | Filing | |
| $55.05 | 2,000 | $110,096.00 | 104,626 | 2025-02-20 | Filing | |
| $54.84 | 1,823 | $99,999.97 | 63,932 | 2025-02-14 | Filing | |
| $54.68 | 1,830 | $100,055.25 | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | $99,560.00 | 82,672 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.33 | 56,000 | $2,650,480.00 | 167,379 | 2025-09-02 | Filing | |
| $44.23 | 378 | $16,718.94 | 5,066 | 2025-08-02 | Filing | |
| $38.01 | 97 | $3,701.83 | 0 | 2025-05-09 | Filing | |
| $55.62 | 700 | $38,930.50 | 11,760 | 2024-11-04 | Filing | |
| $61.25 | 17,986 | $1,101,642.50 | 27,868 | 2023-08-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 198,727,768 | $10,719,375,805 | 0.16% | |
| 2. | 176,825,406 | $9,537,962,416 | 0.16% | |
| 3. | 97,980,438 | $5,285,064,826 | 0.18% | |
| 4. | 75,367,653 | $4,065,331,350 | 0.26% | |
| 5. | 71,322,392 | $3,847,129,825 | 0.6% |
News See All
Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential
On February 20, Barclays began coverage of Bristol-Myers Squibb Company (NYSE:BMY) with an Overweight rating and a $75 price target.
14 Best Low Volatility Dividend Stocks to Invest In
Morgan Stanley’s Global Investment Committee believes the current bull market still has room to run and could extend into a fourth year.
What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)?
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best immunotherapy stocks to buy according to hedge funds.
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
On February 13, Matt Orton, Raymond James Investment Management's chief market strategist, appeared on CNBC’s ‘The Exchange’ to talk about the recent trends in equity markets and what may drive ...
Here's What Analysts Are Saying About Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best medical research stocks to buy according to hedge funds.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under pressure.
Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best long-term stocks to invest in for retirement.
12 Best Long-Term Stocks to Invest in for Retirement
Days are gone when investors simply put money into fixed-income assets for their appealing yields, generating solid streams of income to finance a comfortable retirement.
Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating
On February 6, 2026, Guggenheim raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $72 from $62 and reiterated a Buy rating.
Hedge Fund Resource Center